Evidence map›Paper›PMID 39869599›Full record

ArticlePloS one2025

Site-selective photo-crosslinking for the characterisation of transient ubiquitin-like protein-protein interactions.

Zac Sandy, Zijuan Wang, Deepak Behera, Benjamin M Foster, Finlay A Martin, Kira Brüninghoff, Kathleen M Cain, Wolfgang Dörner, Maria Jose Cabello-Lobato, Josep V Forment and 6 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zac SandyManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Zijuan WangManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Deepak BeheraManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Benjamin M FosterManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.ORCID 0000-0003-0670-2321
Finlay A MartinManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Kira BrüninghoffInstitute of Biochemistry, University of Münster, Münster, Germany.
Kathleen M CainManchester Institute of Biotechnology (MIB), University of Manchester, Manchester, United Kingdom.
Wolfgang DörnerInstitute of Biochemistry, University of Münster, Münster, Germany.
Maria Jose Cabello-LobatoManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Josep V FormentEarly Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Matthew J CliffSchool of Chemistry, University of Manchester, Manchester, United Kingdom.
Igor LarrosaSchool of Chemistry, University of Manchester, Manchester, United Kingdom.
Perdita BarranSchool of Chemistry, University of Manchester, Manchester, United Kingdom.
Duncan L SmithCancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Henning D MootzInstitute of Biochemistry, University of Münster, Münster, Germany.
Christine K SchmidtManchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-8363-7933

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-covalent protein-protein interactions are one of the most fundamental building blocks in cellular signalling pathways. Despite this, they have been historically hard to identify using conventional methods due to their often weak and transient nature. Using genetic code expansion and incorporation of commercially available unnatural amino acids, we have developed a highly accessible method whereby interactions between biotinylated ubiquitin-like protein (UBL) probes and their binding partners can be stabilised using ultraviolet (UV) light-induced crosslinks. The stabilised protein complexes can be purified using affinity purification and identified by mass spectrometry. The resultant covalent bonds can withstand even the harshest washing conditions, allowing for the removal of indirect binders whilst retaining and capturing weak and transient interactors that are commonly lost during wash steps. This technique is widely applicable and highly effective for identifying site-selective non-covalent interactors. Members of our team have previously demonstrated the benefit of this method using the small ubiquitin-like modifier (SUMO). Here, we provide further proof-of-principle validation of the method and highlight its generality by applying an optimised workflow to a lesser studied UBL, interferon stimulated gene 15 (ISG15). We show that this method is able to capture known ISG15 interactors from a complex protein mixture in a site-selective manner, only capturing proteins that specifically interact with the region of ISG15 where the unnatural amino acid was incorporated. This exquisite degree of sensitivity and specificity greatly improves upon previous screens aimed at identifying downstream non-covalent binders, or readers, of ISG15. Taken together, the approach opens the possibility of characterising previously undetected protein-protein interactions, with the potential of elucidating molecular mechanisms behind the most complex and poorly understood processes in the cell.

Indexed as

Cross-Linking ReagentsCytokinesProtein Interaction MappingUbiquitinUbiquitinsBiotinylationHumansProtein BindingUltraviolet RaysCross-Linking ReagentsCytokinesISG15 protein, humanUbiquitinUbiquitins

Identifiers

PMID39869599
PMCPMC11771908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.